spacer
home > pmps > spring 2018 > controlled conduct
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Controlled Conduct

PMPS: Can you explain the current prevalence of counterfeiting within the pharmaceutical industry?

Sandra Lee: The WHO estimate 15% of all medicines available worldwide are counterfeit, and, while this decreases to around 1% in the EU, it remains a significant risk to patient safety. As the demand for prescription medicines continues to rise, incentive and opportunity for counterfeiters to interfere with the legitimate supply chain increases.

Pharma manufacturers have been preparing for the adoption of the Falsified Medicines Directive (FMD), which will be enforced in February 2019, as this will provide added security within the supply chain. The additional safeguards of FMD will help protect against counterfeit medicines potentially reaching critically ill patients, such as the recently reported instances of oncology medicines for cancer patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sandra Lee has 35 years’ plus of operational, quality, and project management experience within the commercial and clinical pharma industry, gained through roles at past organisations such as Novartis, Boehringer Ingelheim, Fisher Clinical Services, and now Accord Healthcare. Currently, as the Managing Director of operations at Accord, she leads the manufacturing sites at Barnstaple and Haverhill. Sandra received her BSc in applied chemistry at Brighton Polytechnic, UK, has a post-graduate diploma in industrial pharmaceutical studies, and is also a Chartered Director.
spacer
Sandra Lee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Expands Services for Early Discovery Screening

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.
More info >>

White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement